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Intermittent calcitriol therapy in secondary hyperparathyroid-
ism: A comparison between oral and intraperitoneal administra-
tion.
Background. Intermittent oral or intravenous doses of calcitriol
given two or three times per week are commonly used to treat
secondary hyperparathyroidism (2° HPT). This study was under-
taken to compare the biochemical and skeletal responses to thrice
weekly intraperitoneal (i.p.) versus oral doses of calcitriol in
children with 2° HPT undergoing peritoneal dialysis (CCPD).
Methods. Forty-six patients aged 12.5 6 4.8 years on CCPD for
22 6 25 months were randomly assigned to treatment with oral
(p.o.) or i.p. calcitriol for 12 months; 17 subjects given p.o.
calcitriol and 16 subjects given i.p. calcitriol completed the study.
Bone biopsies were performed at the beginning and at the end of
the study, while determinations of serum and total ionized
calcium, phosphorus, alkaline phosphatase, parathyroid hormone
(PTH) and calcitriol levels were done monthly.
Results. Serum total and ionized calcium levels were higher in
subjects treated with i.p. calcitriol, P , 0.0001, whereas serum
phosphorus levels were higher in those given p.o. calcitriol, P ,
0.0001. For the i.p. group, serum PTH levels decreased from
pre-treatment values of 648 6 125 pg/ml to a nadir of 169 6 57
pg/ml after nine months. In contrast, serum PTH levels did not
change from baseline values of 670 6 97 pg/ml in subjects given
p.o. calcitriol, P , 0.0001 by multiple regression analysis. Serum
alkaline phosphatase levels were also lower in patients treated
with i.p. calcitriol, P , 0.0001, but there was no difference
between groups in the average dose of calcitriol given thrice
weekly. The skeletal lesions of 2° HPT improved in both groups,
33% of patients developed adynamic bone lesion.
Conclusion. Differences in the bioavailability of calcitriol and/or
in phosphorus metabolism may account for the divergent bio-
chemical response to p.o. and i.p. calcitriol.
Peritoneal dialysis has become the predominant mode of
dialysis in children with end-stage renal disease, but persis-
tent bone disease remains a major challenge in the clinical
management of such patients [1]. Secondary hyperparathy-
roidism is the most common skeletal lesion in pediatric
patients undergoing regular dialysis, and the disorder often
progresses despite treatment with daily doses of oral cal-
citriol [2–5]. As such, alternative therapeutic approaches
have been sought to improve the clinical, biochemical and
histological responses to calcitriol therapy in children with
secondary hyperparathyroidism due to end-stage renal
disease.
Large intermittent doses of calcitriol given two or three
times per week have recently been used to treat secondary
hyperparathyroidism both in children and in adults [6–10].
Most studies have employed the oral or intravenous routes
of administration, but there is little available information
about the effect of intraperitoneal doses of calcitriol on
bone and mineral metabolism in patients undergoing reg-
ular peritoneal dialysis. Increases in blood ionized calcium
levels and reductions in serum PTH values have been
documented in short-term studies [11], but the efficacy of
intraperitoneal doses of calcitriol for the long-term man-
agement of secondary hyperparathyroidism has not been
examined; indeed, the skeletal response to intermittent
calcitriol therapy has yet to be fully characterized either in
adults or in children.
The current randomized clinical trial was undertaken to
prospectively evaluate the biochemical and histological
responses to intermittent calcitriol therapy using thrice
weekly intraperitoneal or oral doses in pediatric patients
with secondary hyperparathyroidism undergoing long-term
peritoneal dialysis. Bone biopsy and quantitative histomor-
phometry of bone were done before and after 12 months of
treatment, and biochemical indices of bone and mineral
metabolism were measured at monthly intervals for the
duration of study.
METHODS
Study design
A total of 46 patients, aged 12.5 6 4.8 years, who were
treated with CCPD for an average of 22 6 25 months were
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evaluated. All study candidates were medically stable pa-
tients between the ages of two and 18 years who had
undergone CCPD for at least two months. For those begun
on dialysis because of acute renal failure, a stabilization
period of at least six months was required before subjects
became eligible for study. Bone biopsy was done in all
potential study candidates to document the type of renal
osteodystrophy using established histologic criteria [2].
Subjects were eligible for randomization if they had bone
biopsy evidence of either secondary hyperparathyroidism
or normal rates of bone formation [2]. Candidates were
excluded from study if they had other skeletal lesions of
renal osteodystrophy such as adynamic lesions, osteomalcia
or mixed skeletal lesions. Those with a documented history
of poor compliance with medical treatment regimens, those
who had undergone parathyroidectomy within the previous
12 months, and patients who had received either pred-
nisone or other immunosuppressive agents while undergo-
ing regular dialysis were also excluded. All study partici-
pants had been treated in the past with daily doses of oral
calcitriol, but therapy was stopped at least four weeks
before beginning intermittent calcitriol therapy. The study
protocol was approved by the UCLA Human Subjects
Protection Committee, and informed consent was obtained
from each patient and from either parents or guardians
where appropriate.
Biochemical determinations were done before starting
treatment and at monthly intervals over the 12 months of
study. These included measurements of serum total and
ionized calcium, phosphorus, alkaline phosphatase, para-
thyroid hormone (PTH) and calcitriol levels. Two separate
baseline PTH determinations were obtained before begin-
ning i.p. or p.o. calcitriol therapy. Blood samples for
monthly biochemical measurements were obtained 24
hours after regular thrice weekly doses of calcitriol during
interval clinic visits. After 12 months of treatment, subjects
underwent a second iliac crest bone biopsy to assess interim
changes in bone histology. Quantitative bone histomor-
phometry was done as previously described [2], and termi-
nology established by the Nomenclature Committee of the
American Society for Bone and Mineral Research was used
to present the results [12].
A total of thirty-three patients completed the 12-month
clinical trial; 17 patients, aged 13.2 6 1.3 years, were
randomly assigned to treatment with oral (p.o.) calcitriol,
and 16 patients, aged 12.5 6 1.1 year, were treated with
intraperitoneal (i.p.) calcitriol. The duration of CCPD was
27 6 15 months (range 3 to 100 months) and 20 6 eight
months (range 3 to 120 months), respectively, in subjects
given p.o. or i.p. calcitriol. Calcium carbonate was used as
the primary phosphate-binding agent in all patients, and
the dose was adjusted monthly, or more often when neces-
sary, according to serum phosphorus levels. The dietary
intake of calcium, phosphorus and other nutrients was
determined for each month of the study using three-day
diet diaries gathered during monthly clinic visits [13]. The
calcium concentration in peritoneal dialysate was 3.5 mEq/
liter for all study subjects.
Patients assigned to oral therapy were given calcitriol
(Rocaltrolt; Hoffman-LaRoche, Nutley, NJ, USA) thrice
weekly for 12 months. Patients assigned to intraperitoneal
therapy received the intravenous form of calcitriol (Calci-
jex®; Abbott Laboratories, Abbott Park, IL, USA) instilled
thrice weekly into the peritoneal cavity with small residual
volumes of peritoneal dialysate after overnight dialysis
exchanges. The technique for intraperitoneal calcitriol ad-
ministration has been described in detail elsewhere [14].
Doses of oral or intraperitoneal calcitriol were given Mon-
days, Wednesdays and Fridays in the morning at the
completion of nightly dialysis treatments. Doses were ad-
justed based upon the results of monthly serum calcium
and phosphorus determinations [7]. The average daily dose
of calcitriol for each month of study and the cumulative
dose of calcitriol for the full 12 months of follow-up were
calculated in each patient.
The initial dose of calcitriol for all subjects was 1.0 mg
thrice weekly, a dosage chosen based upon data reported by
Delmez et al [11] in adult CAPD patients and from our own
experience in pediatric CCPD patients with severe second-
ary hyperparathyroidism. The dose of calcitriol was in-
creased in increments of 0.5 mg each month if serum
calcium levels remained below 10.0 mg/dl and if serum
phosphorus levels were less than 6.0 mg/dl. Calcitriol
therapy was discontinued temporarily if serum calcium
levels exceeded 11.0 mg/dl; treatment was restarted after
reducing the dose by 50% following the resolution of
hypercalcemia.
Patients who developed persistent hypercalcemia with
serum calcium levels above 11.0 mg/dl during concurrent
therapy with calcitriol and calcium carbonate were changed
to dialysate containing 2.5 mEq/liter of calcium. For those
remaining hypercalcemic despite the use of low-calcium
dialysate and reduced doses of calcium carbonate, alumi-
num hydroxide was added as an alternative phosphate-
binding agent [15]. Subjects were withdrawn from study if
hypercalcemia persisted despite these maneuvers.
Doses of calcitriol were also withheld if serum phospho-
rus levels exceeded 7.0 mg/dl, and treatment was resumed
only after serum phosphorus values fell below 6.5 mg/dl.
Subjects who developed persistent hyperphosphatemia
with serum phosphorus levels above 7.5 mg/dl for more
than three months were withdrawn from study. Additional
withdrawal criteria included kidney transplantation, change
in mode of dialysis and psychosocial factors as determined
by medical staff.
Biochemical determinations
Serum total calcium, phosphorus and alkaline phospha-
tase levels and blood ionized calcium levels were measured
by automated methods as previously described [2, 7, 16].
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Serum PTH levels were determined using a two-site immu-
noradiometric assay for the intact hormone (Allegro PTH;
Quest Diagnostics, San Juan Capistrano, CA, USA) [17],
and serum calcitriol levels were measured by radioreceptor
assay (Quest Diagnostics) [18].
Randomization technique and statistical analysis
Patients were randomly assigned to treatment with either
oral or intraperitoneal calcitriol by a biostatistitian using
three randomization schedules, one for each skeletal le-
sion, that is, osteitis fibrosa, mild secondary hyperparathy-
roidism and normal bone formation. Randomization was
done in blocks of four, six or eight with the block length
determined at random.
All results are expressed as mean 6 SE. Comparisons
between groups for pre-treatment characteristics were
done using unpaired t-tests [19]. Changes in bone histomor-
phometric variables in each treatment group were evalu-
ated by paired t-tests, whereas un-paired t-tests were used
to compare histologic outcomes between i.p. and p.o.
therapy [19]. Paired t-tests were used to compare monthly
biochemical values with pre-treatment values within each
treament arm using Bonferroni adjustments for multiple
comparisons.
Because the dose of calcitriol varied over time, dosage
values represent the amount of the sterol given during each
month of study. Additional analyses considered potential
differences in biochemical outcomes between treatment
groups as a function of the dose of calcitriol. Thus, multiple
regression analyses were done with each biochemical de-
termination as an outcome variable using the month of
study, the average calcitriol dose for the corresponding
month of treatment, the average calcitriol dose during the
preceding month and an indicator for treatment group as
predictor variables [19].
RESULTS
The age, sex distribution, primary renal disease and
duration of dialysis prior to study did not differ for patients
given intraperitoneal (i.p.) or oral (p.o.) calcitriol (Table 1).
The number of subjects in each group that had previously
received a renal transplant was also similar (Table 1). None
of the patients had undergone previous parathyroidectomy,
and the rates of peritonitis during study did not differ
between groups (Table 1).
Serum biochemical determinations
Initial total serum calcium levels did not differ between
groups. Values were 9.1 6 0.2 mg/dl for patients given i.p.
calcitriol and 8.5 6 0.3 mg/dl for those treated with p.o.
calcitriol, P 5 NS. Serum calcium levels increased during
the first month of treatment in patients given i.p. calcitriol,
and values remained above pre-treatment levels for most of
the remaining 12 months of study (Fig. 1A). The peak
serum calcium level during i.p. therapy was 10.4 6 0.5
mg/dl; this was observed after 10 months of treatment (Fig.
1A). Serum calcium concentrations also rose in patients
given p.o. calcitriol but only after the fourth month of
treatment; the highest average monthly serum calcium level
was 9.7 6 0.4 mg/dl after ten months of study (Fig. 1A).
Although serum calcium levels at each monthly interval did
not differ between those given i.p. or p.o. calcitriol, values
were greater overall in subjects given i.p. calcitriol when the
results for the full 12 months of study were evaluated by
multiple regression analysis, P , 0.001. Serum albumin
Fig. 1. Serum total (A) and blood ionized (B) calcium levels during 12
months of treatment with intermittent doses of i.p. (F) or p.o. (M)
calcitriol. *P , 0.05 versus pre-treatment values in each group. For the
full 12 months of treatment, levels were greater in i.p. than in p.o.; P ,
0.0001 for total calcium and P , 0.001 for ionized calcium by multiple
regression analysis.
Table 1. Characteristics of patients randomly assigned to treatment
with intraperitoneal (i.p.) or oral (p.o.) doses of calcitriol thrice weekly
i.p.
(N 5 16)
p.o.
(N 5 17)
Number of patients (M/F) 9/7 9/8
Age years 12.5 6 1.1 13.2 6 1.3
Duration of dialysis months 21 6 8 27 6 15
Primary renal disease
Obstructive/dysplastic 3 6
Glomerular 5 9
Interstitial 4 —
Unknown 4 2
Previous kidney transplant 2 4
Values are means 6 SE.
Salusky et al: Intermittent calcitriol therapy in 2° HPT 909
levels did not differ between groups; initial values were
3.75 6 0.12 and 3.65 6 0.11 g/liter, respectively, in subjects
given i.p. or p.o. calcitriol.
Pre-treatment blood ionized calcium levels also did not
differ between subjects given i.p., 1.20 6 0.02 mmol/liter, or
p.o., 1.17 6 0.05 mmol/liter, calcitriol (NS), and monthly
values did not change from baseline values in either group
except at month seven in those given i.p. calcitriol (Fig. 1B).
By multiple regression analysis, however, blood ionized
calcium levels during the full 12-month study were higher in
patients treated with i.p. calcitriol (P , 0.001). Dietary
calcium intake did not differ between groups; values were
435 6 36 mg/day in patients receiving i.p. calcitriol and
499 6 41 mg/day in those given p.o. calcitriol (NS).
Pre-treatment serum phosphorus levels averaged 6.2 6
0.3 and 6.4 6 0.3 mg/dl, respectively, in subjects treated
with i.p. or p.o. calcitriol, NS. Serum phosphorus levels
remained stable or decreased during i.p. calcitriol therapy,
and none of the average monthly values exceeded pre-
treatment levels (Fig. 2). Indeed, serum phosphorus values
fell below baseline values during the third, sixth and
seventh month of treatment (Fig. 2). Serum phosphorus
levels exceeded pre-treatment values during the second,
fifth, seventh and twefth months of p.o. calcitriol therapy,
although these changes were not significantly greater than
baseline values (Fig. 2). Multiple regression analysis indi-
cated that serum phosphorus levels over the 12 months of
study were higher in patients given p.o. calcitriol despite
similar levels of dietary phosphorus intake (P , 0.0001).
Phosphorus intake throughout the study averaged 712 6 52
and 779 6 45 mg/day for patients given i.p. or p.o. calcitriol,
respectively.
Serum PTH levels before treatment did not differ be-
tween groups (Fig. 3A). For those treated with i.p. calci-
triol, serum PTH levels decreased by 62% from pre-
treatment values of 648 6 125 pg/ml within the first month
of study, reaching a nadir value of 169 6 57 pg/ml after nine
months of therapy. In contrast, serum PTH levels did not
change from pre-treatment levels of 670 6 97 pg/ml during
p.o. calcitriol therapy (Fig. 3A). Although average monthly
serum PTH values did not differ between groups, PTH
levels were generally higher in those given p.o. calcitriol
when multiple regression analysis was used to evaluate the
results for the full 12 months of study (P , 0.0001).
Serum alkaline phosphatase levels were initially similar
in each treatment group (Fig. 3B). Alkaline phosphatase
levels decreased, however, in subjects given i.p. calcitriol,
whereas values remained unchanged in those receiving p.o.
calcitriol (Fig. 3B). Overall, serum alkaline phosphatase
levels were substantially greater in patients given oral
calcitriol when evaluated by multiple regression analysis
(P , 0.0001).
Dose of calcitriol and episodes of hypercalcemia and
hyperphosphatemia
Serum calcitriol levels were subnormal before treatment,
but baseline values did not differ between patients random-
ized to i.p. (12 6 6 pg/ml, or p.o., 10 6 4 pg/ml, calcitriol
therapy; NS). Monthly serum calcitriol levels were within
the normal range in both groups during treatment, and
there were no differences between groups (Fig. 4). The
dose of calcitriol for the full 12 months of study averaged
1.3 6 0.08 mg/dose for patients treated with i.p. calcitriol
and 1.5 6 0.9 mg/dose for those given p.o. calcitriol; these
Fig. 2. Serum phosphorus levels during 12 months of treatment with
intermittent doses of i.p. or p.o. calcitriol. *P , 0.05 versus pre-treatment
values in each group. For the 12 months of treatment, values were greater
in p.o. (M) than in i.p. (F), P , 0.001 by multiple regression analysis.
Fig. 3. Serum PTH (A) and alkaline phosphatase levels (B) during 12
months of treatment with intermittent doses of i.p. (F) or p.o. (M)
calcitriol. *P , 0.05 versus pre-treatment values in each group. For the 12
months of treatment, values were greater in i.p. than in p.o.; P , 0.001 for
PTH and P , 0.001 for alkaline phosphatase by multiple regression
analysis.
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values did not differ. During the final three months of
study, patients given p.o. calcitriol received the highest
average monthly dose.
There were 18 episodes of hypercalcemia, defined by a
serum calcium value above 11.0 mg/dl, in eight subjects
given i.p. calcitriol, whereas eight episodes occurred in five
patients treated with p.o. calcitriol (NS by x2 analysis).
When defined as a serum phosphorus level exceeding 7.0
mg/dl, thirteen episodes of hyperphosphatemia occurred in
two patients given i.p. calcitriol, whereas 18 episodes were
seen in three subjects receiving p.o. calcitriol (NS).
Changes in bone histology during intermittent calcitriol
therapy
The skeletal lesions of secondary hyperparathyroidism
improved after 12 months of treatment in both groups (Fig.
5). Osteitis fibrosa persisted in two patients given i.p.
calcitriol, and the extent of marrow fibrosis in both subjects
was less at follow-up examination than before treatment.
Three subjects with osteitis fibrosa prior to treatment with
i.p. calcitriol had mild lesions of secondary hyperparathy-
roidism without peri-trabecular or marrow fibrosis at the
end of study, whereas four had normal rates of bone
formation; two subjects developed adynamic lesions of
renal osteodystrophy (Fig. 5). For those given p.o. calci-
triol, osteitis fibrosa resolved in seven of 12 patients,
whereas the extent of marrow fibrosis diminished in five.
Three subjects with osteitis fibrosa developed adynamic
renal osteodystrophy during p.o. calcitriol therapy (Fig. 5).
After 12 months of intermittent calcitriol therapy, bone
formation was normal or reduced in 11 of 16 patients given
i.p. calcitriol and in 11 of 17 subjects treated with p.o.
calcitriol. The magnitude of the reduction in bone forma-
tion did not differ between groups; values decreased by an
average of 67% in patients given i.p. calcitriol and by 54%
in those treated with p.o. calcitriol, NS (Table 2).
DISCUSSION
The results of the current randomized, prospective clin-
ical trial indicate that intermittent doses of calcitriol given
either orally or intraperitoneally markedly improve the
skeletal lesions of secondary hyperparathyroidism in a large
proportion of pediatric patients undergoing regular perito-
neal dialysis. As noted in earlier reports [7, 20], bone
formation decreases substantially during intermittent cal-
citriol therapy, and adynamic lesions of renal osteodystro-
phy often develop [7]. Unfortunately, biochemical indices
of bone and mineral metabolism are only moderately good
predictors of the skeletal response to intermittent calcitriol
therapy, particularly when doses are given orally. Thus,
serum PTH and alkaline phosphatase levels declined sub-
stantially during treatment with i.p. calcitriol, but similar
reductions were not observed in subjects given p.o. calci-
triol despite equivalent decreases in bone formation and
comparable improvements in bone histology. These dis-
crepancies were apparent despite the lack of differences
between groups in the pre-treatment values for serum PTH
and alkaline phosphatase, in the average dose of calcitriol
utilized and in the dietary intake of either calcium or
phosphorus. The results suggest that the biochemical indi-
ces commonly used to monitor calcitriol therapy do not
reliably reflect changes in bone formation and turnover
during treatment with large intermittent oral doses of
calcitriol.
For subjects given i.p. calcitriol, serum calcium levels
increased within the first few months of study, and this
change was associated with concordant reductions in serum
PTH and alkaline phosphatase levels. In contrast, serum
calcium levels did not rise above baseline values until the
fifth month of study in subjects treated with p.o. calcitriol,
and serum PTH and alkaline phosphatase levels remained
unchanged during follow-up. Although neither the monthly
dose of calcitriol nor the cumulative dose over the full 12
months of study differed between groups, the adequacy of
control of serum phosphorus levels during intermittent
calcitriol therapy may have contributed to these divergent
results.
Phosphorus retention and hyperphosphatemia have long
been recognized as important factors in the pathogenesis of
secondary hyperparathyroidism due to chronic renal failure
Fig. 4. The serum levels of 1,25-dihydroxyvitamin D (A) and the average
thrice weekly dose of calcitriol (B) during 12 months of treatment with
intermittent doses of i.p. (f) or p.o. (E). *P , 0.05 versus pre-treatment
value for each group.
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[21]. More recently, several groups of investigators have
presented evidence to suggest that phosphorus can directly
influence PTH gene transcription and/or message transla-
tion, leading to increases in PTH synthesis [22–24]. In the
current study, serum phosphorus levels were generally
higher in subjects receiving p.o. calcitriol; as such, differ-
ences in the degree of compliance with phosphate-binding
medications or differences in dietary phosphorus intake
could account for the persistently higher serum PTH levels
in subjects treated with p.o. calcitriol. The amount of
dietary phosphorus ingested did not differ, however, be-
tween subjects given i.p. or p.o. calcitriol, and both groups
were repeatedly counseled during monthly clinic visits
about the ongoing requirement for phosphate-binding ther-
apy. Serum calcitriol levels increased from pre-treatment
values in both groups, and serum calcitriol levels were
maintained within the normal range for the full duration of
study; indeed, serum calcitriol levels did not differ between
groups at any monthly interval during treatment. Such
findings provide biochemical evidence that study partici-
pants received a substantial amount of prescribed doses of
calcitriol. Although sub-optimal medical compliance can-
not be fully excluded, the results suggest that the oral route
of calcitriol administration may result in disproportionate
increases in intestinal phosphorus transport and that this
change accounts for greater increases in serum phosphorus
levels in patients treated with large intermittent dose of
oral calcitriol [25].
Previous short-term studies have also shown that serum
calcitriol levels and sterol bioavailability vary with the route
of calcitriol administration [26]. Serum calcitriol levels are
higher during the initial three to six hours and the bioavail-
ability of calcitriol is 50 to 60% greater within the first 24
hours following single intravenous doses when results are
compared to those obtained after equivalent oral or intra-
peritoneal doses [26]. The bioavailability of calcitriol does
not differ, however, between the oral and intraperitoneal
routes of administration when injectable calcitriol is added
to conventional large-volume peritoneal dialysate ex-
changes [26].
In the current study, a modified technique was used for
intraperitoneal calcitriol administration to diminish adher-
ence of the sterol to the plastic materials that comprise
peritoneal dialysate delivery systems; thus, injectable cal-
citriol was instilled directly into the peritoneal cavity with
only 50 to 100 ml of dialysate at the end of overnight
dialysate exchanges [14]. This modified approach may have
reduced the amount of each dose lost by binding to plastic
Fig. 5. The histological sub-types of renal
osteodystrophy before and after 12 months of
intermittent i.p. (A) or p.o. (B). Abbreviations
are: OF, osteitis fibrosa; mild, mild secondary
hyperparathyroidism; normal, bone formation
rate within the normal range [2].
Table 2. Rate of bone formationa before and after 12 months of
intermittent intraperitoneal (i.p.) or oral (p.o.) calcitriol therapy
i.p.
(N 5 16)
p.o.
(N 5 17)
Before 894 6 111 1272 6 143b
After 297 6 118 586 6 236
Values are means 6 SE.
a Range of normal, 98 to 613 mm2/mm2/day
b P , 0.05 vs. i.p.
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dialysis supplies, thereby increasing the fraction of the dose
available for absorption across the peritoneal membrane
[26]. Although the serum levels of calcitriol at each monthly
interval did not differ between groups when measured 24
hours after the previous dose, earlier work has demon-
strated that the greater bioavailability of calcitriol after
intravenous administration is not associated with higher
serum levels compared to oral doses when calcitriol levels
are determined 24 hours after single doses [26]. As such,
differences in the bioavailabilty of calcitriol between treat-
ment groups may have contributed to the disparities noted
in the current study for several biochemical parameters of
mineral metabolism during intermittent calcitriol therapy.
The discrepancy between persistently elevated serum
PTH levels and markedly reduced rates of bone formation
during intermittent calcitriol therapy underscores the lim-
itation of using single, isolated serum PTH determinations
as a predictor of bone histology in patients with renal
osteodystrophy, particularly during intermittent calcitriol
therapy. Although the immunoradiometric assay (IRMA)
for intact parathyroid hormone is a useful non-invasive tool
for distinguishing among various subtypes of renal os-
teodystrophy both in adults and in children, these results
have been obtained from cross-sectional studies of un-
treated patients or from assessments of those treated with
small daily doses of oral calcitriol [3, 5, 27–29]. Others,
however, have reported considerable discord between the
serum PTH levels and bone histology in patients undergo-
ing regular dialysis [30], and some have suggested that
serum alkaline phosphatase values or serum osteocalcin
levels provide better indices of bone formation activity in
patients with end-stage renal disease. Considerable short-
term variations in serum PTH levels due to pulsatile PTH
secretion could, in part, account for these results; more-
over, Seidel et al demonstrated that serum PTH levels are
reduced for up to 72 hours after large, single doses of
calcitriol [31]. Such findings indicate that additional infor-
mation is needed about short-term variations in serum
PTH levels and about the impact of intermittent calcitriol
dosage regimens on serum PTH values in patients with
end-stage renal disease to more fully understand the rela-
tionship between parathyroid gland activity and bone turn-
over in renal osteodystrophy. These issues are particularly
important for the longitudinal follow-up of patients under-
going intermittent calcitriol therapy.
Despite substantial differences in the biochemical re-
sponse to i.p. and p.o. calcitriol therapy, bone histology
improved in most study participants regardless of the route
of calcitriol administration. Twenty-seven percent of these
subjects had normal rates of bone formation documented
by bone biopsy after 12 months of treatment, but 33%
developed adynamic lesions of renal osteodystrophy. Over-
all, the magnitude of the reduction in bone formation did
not differ between groups. As noted previously by Andress
et al [20], the percentage decrease in bone formation
exceeded the percentage change in bone resorption as
measured by the extent of eroded surface in cancellous
bone. Thus, intermittent calcitriol therapy was associated
with a disproportionate inhibitory effect on osteoblastic
activity in both treatment groups. Such findings are consis-
tent with earlier observations indicating that intermittent
calcitriol therapy lowers osteoblastic activity and bone
formation by a mechanism that is distinct from that medi-
ated by vitamin D-induced reductions in serum PTH levels
[7]. Indeed, growth velocity diminished in patients that
developed the adynamic lesions of renal osteodystrophy
after intermittent calcitriol therapy [32]. It may be prudent,
therefore, to withhold therapy with calcitriol if serum PTH
(intact molecule) levels are less than 200 pg/ml in pediatric
patients undergoing maintenance dialysis to diminish the
risk of developing adynamic bone.
In summary, intermittent calcitriol therapy reverses
many of the histological abnormalities of secondary hyper-
parathyroidism in pediatric patients undergoing regular
peritoneal dialysis. Favorable results were obtained after 12
months of treatment with either oral or intraperitoneal
doses of calcitriol using a thrice weekly dosage regimen,
and there were no differences between groups in the
skeletal response to intermittent calcitriol therapy. In con-
trast, the biochemical indices of bone and mineral metab-
olism, such as serum PTH and alkaline phosphatase levels,
that are widely used to monitor the evolution of bone
disease in patients with chronic renal failure do not accu-
rately reflect decreases in bone formation during intermit-
tent oral calcitriol therapy. Differences in sterol bioavail-
ability and in phosphorus metabolism between subjects
treated with oral or intraperitoneal doses of calcitriol may
contribute to the divergent biochemical response to these
two forms of therapy in patients with secondary hyperpara-
thyroidism.
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